stoxline Quote Chart Rank Option Currency Glossary
BioNexus Gene Lab Corp. (BGLC)
0.77  -0.02 (-2.53%)    12-08 15:59
Open: 0.7653
High: 0.8448
Volume: 331,124
Pre. Close: 0.79
Low: 0.7504
Market Cap: 14(M)
Technical analysis
2023-12-08 4:41:54 PM
Short term     
Mid term     
Targets 6-month :  1.29 1-year :  1.86
Resists First :  1.1 Second :  1.6
Pivot price 0.68
Supports First :  0.31 Second :  0.25
MAs MA(5) :  0.73 MA(20) :  0.59
MA(100) :  1.1 MA(250) :  0.81
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  33.7 D(3) :  32.3
RSI RSI(14): 55.8
52-week High :  9.48 Low :  0.07
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ BGLC ] has closed below upper band by 40.4%. Bollinger Bands are 48.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.85 - 0.85 0.85 - 0.85
Low: 0.74 - 0.75 0.75 - 0.75
Close: 0.76 - 0.77 0.77 - 0.78
Company Description

BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Headline News

Mon, 27 Nov 2023
US Stocks Lower; Dow Falls Over 50 Points - BioNexus Gene Lab (NASDAQ:BGLC), Biodexa Pharmaceuticals (NAS - Benzinga

Fri, 24 Nov 2023
US Stocks Mixed; Dow Gains 50 Points - BioNexus Gene Lab (NASDAQ:BGLC), (NASDAQ:AMZN) - Benzinga

Mon, 20 Nov 2023
BioNexus Gene Lab Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 -

Mon, 16 Oct 2023
BioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as A Director -

Wed, 23 Aug 2023
Why Is BioNexus Gene Lab (BGLC) Stock Up 33% Today? - InvestorPlace

Wed, 16 Aug 2023
BioNexus Gene Lab Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 -

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Diagnostics & Research
Shares Out 18 (M)
Shares Float 10 (M)
Held by Insiders 58.8 (%)
Held by Institutions 0 (%)
Shares Short 24 (K)
Shares Short P.Month 23 (K)
Stock Financials
EPS -0.28
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.54
Profit Margin -30 %
Operating Margin -99 %
Return on Assets (ttm) -15.2 %
Return on Equity (ttm) -38.5 %
Qtrly Rev. Growth -0.9 %
Gross Profit (p.s.) 0
Sales Per Share 0.58
EBITDA (p.s.) -0.13
Qtrly Earnings Growth 0 %
Operating Cash Flow -1 (M)
Levered Free Cash Flow 1 (M)
Stock Valuations
PE Ratio -2.86
PEG Ratio 0
Price to Book value 1.42
Price to Sales 1.31
Price to Cash Flow -23.84
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android